PubMed Health⌕ Search

Biomedical subjects

G Ia Shvarts

Publications and source records attributed to G Ia Shvarts.

12 recordsLinked to original sources
PubMed1991

[Potential of the anticholinergic drug troventol in the treatment and diagnosis of bronchial asthma].

A study was made of potentialities of the Soviet drug troventol in the diagnosis and treatment of bronchial asthma. 143 patients suffering from bronchial asthma and 38 patients with pollenosis were examined for external respiratory function using a microprocessor spiroanalyzer, the immunological status and clinical symptoms. The importance of carrying out the diagnostic test with troventol in revealing latent bronchospasm was established, the bronchodilatory effect of troventol at the level of the large bronchi was demonstrated as was a decrease of the emotional manifestations together with the immunomodulatory effect. Beneficial results were attained in 67.8% of cases, satisfactory in 16.8%, and unsatisfactory in 15.4%. Untoward effects in the form of tachycardia were recorded in 3.5% of patients, bradycardia in 5.6%, dry mouth in 16.1% of patients.

Asthma↗
PubMed1979

[Effect of antihistaminics on bradykinin action].

On isolated ileum of the guinea pig the antihistamine drugs dimedrol, diprazin (pipolphen), tavegil and suprastin diminished spasmogenic effects of bradykinin and an enhancement of microvascular permeability induced by this polypeptid. The antihistamine drugs display a nonspecific antibradykinin activity. No relationship between the chemical structure and pronounced antibradykinin action of the antihistamines studied was revealed.

Aminopyridines↗
PubMed1979

[Experimental studies of parmidin (pyridinolcarbamate) effect on microvascular permeability of the lungs, skin and mesentery].

The effect of parmidin (pyridinolcarbamate) on microvascular permeability of several organs has been studied on experimental mice and rats using different models of increased vascular permeability, returned to normal by the drug due to its antibradykinine properties. The experimental results correlate with the clinical data on parmidin applied in therapy of a number of diseases associated with abnormal microcirculation.

Animals↗
PubMed1978

[Mechanism of action and clinical effectiveness of the new Soviet-made drug parmidin in the treatment of arteriosclerosis and ischemic heart disease].

The pharmacodynamics and efficacy of the new Soviet drug parmidin depending on the state of the coronary reserve are discussed on the basis of the results of observation over 176 patients suffering from chronic ischemic heart disease with affection of the peripheral arteries of the lower extremities. The activity of the drug in patients with atherosclerotic and diabetic affection of the arterial vessels is shown. The pharmacokinetics of parmidin in patients after the administration of a single 1.0 g dose was studied by determining its content in blood and urine 1, 2, 4, 8, 12, and 24 hours later. The effect of parmidin on the blood kinin system in patients with chronic ischemic heart disease was studied.

Adolescent↗
PubMedDate not supplied

[Experimental study of the anti-inflammatory action of pyridinolcarbamate].

When used in doses of 20-50 mg/kg on models of acute exudative and chronic propliferative inflammation in rats pyridinolcarbamate inhibited the development of an exudative reaction provoked by bradykinine and silver nitrate and did not influence the effects of histamine and dextran, nor the chronic proliferative inflammatory process. As concerns its antiexudative action pyridinolcarbamate is superior to butadion. The effect of the drug comes from its selective antibradykinine action.

Animals↗
PubMedDate not supplied

[Effect of pyridinolcarbamate (parmidine) on some bradykinin effects].

The influence of pyridinolcarbamate (parmidine) on raising the tonicity of bronchial and intestinal muscles in guinea pigs, and also on the edema of the paw in rats, induced with bradykinin was studied. Parmidin displays a specific antibradykinin activity and mitigates the effects of bradykinin in all the objects under investigation, without exercising any influence on the spasmogenic action of histamine, serotonin and acetylcholine.

Animals↗
PubMedDate not supplied

[The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].

In experiments on conscious normotensive male Wistar rats the new antidepressants, reversible MAO-A inhibitors, pyrazidole and incazane, as well as moclobemid increased the pressor effect of orally administered tyramine. The drugs potentiated also the pressor effect of intravenous tyramine. More prolonged potentiation of tyramine action was produced by moclobemid, less prolonged by incazane. The potentiation by the studied MAO-A inhibitors of the pressor effect of tyramine reflects the inhibition of the activity of MAO-A and the first-pass metabolism of tyramine in the gut and liver, as well as the inhibition of intraneuronal MAO activity in noradrenergic nerve endings and the potentiation of sympathetic activity.

Animals↗
PubMedDate not supplied

[The influence of calcium ion antagonists on the effects of bradykinin].

On the isolated segments of the ileum of the guinea-pig, anesthetized and nonanesthetized rats and mice it was established that calcium ion antagonists from different chemical series exert the nonspecific antibradykinin action, reducing the main biological effects of bradykinin--myotropic, depressor, nociceptive and microcirculatory. To a greater extent the mentioned properties show up in the derivatives of 1,4-dihydropyridine (phoridon, etc.) that may play the certain role in the therapeutic action of the drugs in the diseases associated with the activation of the kinin system of the organism.

Animals↗
PubMedDate not supplied

[Effect of tropaphene and fentolamin on the spasmogenic effects of adrenaline, noradrenaline, serotonin and other biologically active substances].

Tests conducted in vitro and in vivo demonstrated that tropaphen, tropine ether of alpha-phenyl-beta-(p-acetoxyphenyl)-propionic acid, an original alpha-adrenoblocking agent, display a marked antiserotonin activity exceeding that of phentolamine. Moreover, tropaphen is more active that phenolamine by its inhibiting influence on the spasmogenous effects of histamine, angiotensin, bradykinine and prostaglandin E2. In doses of 0.1 and 0.25 mg/kg both drugs had no effect on changes of the arterial pressure in anesthetized rats, caused by the above mentioned biologically active substances.

Adrenergic alpha-Antagonists↗
PubMedDate not supplied

[Antihistaminic and antiserotonin properties of new complex tropine esters].

The antihistaminic and antiserotonin properties of 16 new tropine esters, analogues of atropine, tropacin and tropaphen, were studied. All of them were found to lessen the spasmogenic effects of histamine and serotonin. The intensity of the antihistaminic and antiserotonin action of the drugs varied depending upon the structure of the radical at the alpha-carbon atom in the acidic part of the molecule. Both types of the activity are most marked in the desoxymethyl propyl and butyl analogues of atropine. The absence of the oxymethyl group at alpha-carbon in the series of atropine analogues is shown to facilitate the manifestation of the antihistaminic activity.

Animals↗